mimedx group inc. - MDXG

MDXG

Close Chg Chg %
3.95 -0.03 -0.76%

Closed Market

3.92

-0.03 (0.76%)

Volume: 1.68M

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Company Overview: mimedx group inc. - MDXG

MDXG Key Data

Open

$3.87

Day Range

3.81 - 3.94

52 Week Range

3.77 - 7.99

Market Cap

$582.38M

Shares Outstanding

148.57M

Public Float

116.83M

Beta

1.65

Rev. Per Employee

N/A

P/E Ratio

12.08

EPS

$0.33

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.10M

 

MDXG Performance

1 Week
 
2.89%
 
1 Month
 
-12.89%
 
3 Months
 
-35.74%
 
1 Year
 
-44.48%
 
5 Years
 
-69.18%
 

MDXG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About mimedx group inc. - MDXG

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

MDXG At a Glance

MiMedx Group, Inc.
1775 West Oak Commons Court NE
Marietta, Georgia 30062
Phone 1-770-651-9100 Revenue 418.63M
Industry Medical Specialties Net Income 48.58M
Sector Health Technology 2025 Sales Growth 19.993%
Fiscal Year-end 12 / 2026 Employees 808
View SEC Filings

MDXG Valuation

P/E Current 12.084
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 20.869
Price to Sales Ratio 2.421
Price to Book Ratio 3.908
Price to Cash Flow Ratio 13.70
Enterprise Value to EBITDA 11.046
Enterprise Value to Sales 2.078
Total Debt to Enterprise Value 0.026

MDXG Efficiency

Revenue/Employee 518,106.436
Income Per Employee 60,121.287
Receivables Turnover 5.53
Total Asset Turnover 1.38

MDXG Liquidity

Current Ratio 4.318
Quick Ratio 3.923
Cash Ratio 2.585

MDXG Profitability

Gross Margin 82.223
Operating Margin 15.261
Pretax Margin 15.828
Net Margin 11.604
Return on Assets 16.017
Return on Equity 21.607
Return on Total Capital 17.406
Return on Invested Capital 19.751

MDXG Capital Structure

Total Debt to Total Equity 8.783
Total Debt to Total Capital 8.074
Total Debt to Total Assets 6.576
Long-Term Debt to Equity 7.684
Long-Term Debt to Total Capital 7.063
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Mimedx Group Inc. - MDXG

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
267.84M 321.48M 348.88M 418.63M
Sales Growth
+3.57% +20.03% +8.52% +19.99%
Cost of Goods Sold (COGS) incl D&A
50.55M 56.49M 61.71M 74.42M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.30M 3.43M 3.04M 14.88M
Depreciation
4.60M 2.67M 2.28M 2.26M
Amortization of Intangibles
701.00K 762.00K 765.00K 12.62M
COGS Growth
+8.28% +11.76% +9.23% +20.60%
Gross Income
217.29M 264.99M 287.17M 344.21M
Gross Income Growth
+2.53% +21.95% +8.37% +19.86%
Gross Profit Margin
+81.13% +82.43% +82.31% +82.22%
2022 2023 2024 2025 5-year trend
SG&A Expense
230.09M 222.69M 236.56M 280.32M
Research & Development
22.54M 12.36M 12.01M 14.70M
Other SG&A
207.55M 210.33M 224.54M 265.62M
SGA Growth
+7.96% -3.21% +6.23% +18.50%
Other Operating Expense
- 12.18M 5.18M (8.70M)
Unusual Expense
- - - 1.85M
-
EBIT after Unusual Expense
(24.97M) 37.12M 57.47M 63.89M
Non Operating Income/Expense
(4.00K) (26.00K) 2.37M 4.16M
Non-Operating Interest Income
- - 2.93M 4.72M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.02M 6.46M 2.54M 1.78M
Interest Expense Growth
+0.72% +28.73% -60.69% -29.75%
Gross Interest Expense
5.02M 6.46M 2.54M 1.78M
Interest Capitalized
- - - -
-
Pretax Income
(29.99M) 30.63M 57.29M 66.26M
Pretax Income Growth
-198.77% +202.14% +87.03% +15.65%
Pretax Margin
-11.20% +9.53% +16.42% +15.83%
Income Tax
206.00K (36.81M) 15.30M 17.68M
Income Tax - Current - Domestic
- 206.00K 2.82M 8.95M
Income Tax - Current - Foreign
- - - 23.00K
-
Income Tax - Deferred - Domestic
- - 12.47M 8.71M
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(30.20M) 67.44M 42.00M 48.58M
Minority Interest Expense
- - - -
-
Net Income
(30.20M) 67.44M 42.00M 48.58M
Net Income Growth
-193.60% +323.33% -37.72% +15.67%
Net Margin Growth
-11.27% +20.98% +12.04% +11.60%
Extraordinaries & Discontinued Operations
- - (9.21M) 421.00K
-
Discontinued Operations
- - (9.21M) 421.00K
-
Net Income After Extraordinaries
(30.20M) 58.23M 42.42M 48.58M
Preferred Dividends
- - 6.58M 11.64M
-
Net Income Available to Common
(36.78M) 46.59M 42.42M 48.58M
EPS (Basic)
-0.3257 0.3999 0.2886 0.3287
EPS (Basic) Growth
-118.88% +222.78% -27.83% +13.89%
Basic Shares Outstanding
112.91M 116.50M 146.98M 147.79M
EPS (Diluted)
-0.3257 0.3192 0.2846 0.3244
EPS (Diluted) Growth
-118.88% +198.00% -10.84% +13.98%
Diluted Shares Outstanding
112.91M 145.96M 149.05M 149.72M
EBITDA
(19.67M) 40.54M 62.35M 78.77M
EBITDA Growth
-1,752.61% +306.16% +53.80% +26.32%
EBITDA Margin
-7.34% +12.61% +17.87% +18.82%

Snapshot

Average Recommendation BUY Average Target Price 9.667
Number of Ratings 6 Current Quarters Estimate 0.013
FY Report Date 06 / 2026 Current Year's Estimate 0.124
Last Quarter’s Earnings -0.02 Median PE on CY Estimate N/A
Year Ago Earnings 0.32 Next Fiscal Year Estimate 0.25
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate 0.01 0.05 0.12 0.25
High Estimates 0.03 0.06 0.16 0.30
Low Estimate -0.01 0.04 0.07 0.19
Coefficient of Variance 131.99 20.47 31.48 17.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 5
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Mimedx Group Inc. in the News